MedTrace Logo

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

NCT04544748 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-03-06

No results posted yet for this study

Summary

It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Melanoma

Interventions

BIOLOGICAL

GNR-051

Anti-PD1 monoclonal antibody

Sponsors & Collaborators

  • AO GENERIUM

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2022-11-07
Completion
2025-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04544748 on ClinicalTrials.gov